Responses
Immunotherapy biomarkers
Original research
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
